Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Sandra L TunisRalph Aquila

Abstract

This randomized, open-label trial was designed to help inform antipsychotic treatment policies. It compared the 1-year cost-effectiveness of initial treatment with olanzapine (OLZ) (n = 229) versus a "fail-first" algorithm on conventional antipsychotics (then olanzapine if indicated) (CON) (n = 214); and versus initial treatment with risperidone (RIS) (n = 221). Individuals with schizophrenia or schizoaffective disorder were recruited from May 1998 to September 2001. Clinical, functioning, and resource utilization data were collected at baseline and five postbaseline visits. Brief Psychiatric Rating Scale scores defined "clinical effectiveness;" Lehman Quality of Life Scale social relations scores defined "social effectiveness." Requiring failure on less expensive antipsychotics before use of olanzapine did not result in total cost savings, despite significantly higher antipsychotic costs with OLZ. Total 1-year mean costs were 21,283 dollars for CON; 20,891 dollars for OLZ; and 21,347 dollars for RIS (pair-wise comparisons nonsignificant). Intent-to-treat effectiveness comparisons (nonsignificant) were augmented by analyses that adjusted for duration on initial antipsychotic treatment, and by comparisons of patients remaining o...Continue Reading

References

Nov 21, 1990·JAMA : the Journal of the American Medical Association·D A RegierF K Goodwin
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Aug 1, 1967·Journal of Chronic Diseases·D Schwartz, J Lellouch
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1995·Schizophrenia Bulletin·P J Weiden, M Olfson
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Jun 1, 1997·The American Journal of Psychiatry·N WolffJ K Tebes
Jun 3, 1999·Annual Review of Public Health·P DiehrD Y Lin
May 29, 2001·Psychiatric Services : a Journal of the American Psychiatric Association·L DixonA Lehman
Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Patricia ThiedaJohn Kane
Apr 29, 2003·The Journal of Clinical Psychiatry·Dennis A RevickiUNKNOWN Depakote Comparator Study Group
Apr 30, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Joseph MenzinJohn R Lloyd
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Robert RosenheckUNKNOWN Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine
Dec 9, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Gerard W K HugenholtzAntoine C G Egberts
Jan 15, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·P Joseph GibsonJanet L Ramsey
Jan 27, 2004·The Annals of Pharmacotherapy·Gordon G LiuXuemei Luo
Feb 26, 2004·Obesity Research·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Jun 17, 2004·JAMA : the Journal of the American Medical Association·Allison A HedleyKatherine M Flegal
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Peter J WeidenJulie Locklear
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·S L TunisR A Browne

❮ Previous
Next ❯

Citations

Sep 29, 2007·Advances in Therapy·Edward KimAndrei Pikalov
Sep 22, 2007·Journal of Biopharmaceutical Statistics·Douglas FariesMark Belger
Feb 9, 2012·Schizophrenia Bulletin·Edward Chia-Cheng LaiChia-Yin Lin
Jan 12, 2010·BMC Psychiatry·Haya Ascher-SvanumRobert R Conley
Oct 6, 2010·BMC Psychiatry·Allen W NyhuisBruce J Kinon
Apr 29, 2008·BMC Psychiatry·Erik Johnsen, Hugo A Jørgensen
May 29, 2009·Cost Effectiveness and Resource Allocation : C/E·Douglas E FariesHaya Ascher-Svanum
Sep 2, 2010·Applied Health Economics and Health Policy·Marja HensenBen van Hout
Jan 1, 2008·The International Journal of Biostatistics·Sengwee Toh, Miguel A Hernán
Mar 1, 2012·Journal of Comparative Effectiveness Research·Don P BueschingMarc L Berger
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Apr 10, 2008·Current Medical Research and Opinion·Douglas E FariesBruce J Kinon
Jan 30, 2007·Current Medical Research and Opinion·Sandra L TunisBruce J Kinon
Apr 16, 2014·Current Medical Research and Opinion·Marie-Hélène LafeuillePatrick Lefebvre
Nov 28, 2012·Psychology and Psychotherapy·Lisa WoodGillian Haddock
Sep 12, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Anirban Basu
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Bart HeegBen van Hout
Nov 18, 2006·Journal of Clinical Psychopharmacology·David A SmelsonHaya Ascher-Svanum
Jul 25, 2017·Journal of Managed Care & Specialty Pharmacy·Yujin ParkJohn Ko
Jan 23, 2018·The Cochrane Database of Systematic Reviews·Henk S TemminghDan J Stein
Jan 21, 2011·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Jan 1, 2008·Applied Health Economics and Health Policy·Joep DamenMickael Lothgren
Apr 9, 2009·Cost Effectiveness and Resource Allocation : C/E·Nicolas M FuriakSteven D Culler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here